In the MR analysis, after Bonferroni correction (p<0.05/11), we observed that SGLT2 inhibition was associated with a lowered risk of Interstitial lung disease (OR: 0.054, 95% CI: 0.020–0.148, p = 1.31×10-8), Pulmonary tuberculosis (OR: 0.280, 95% CI: 0.123–0.639, p = 2.48×10-3), Pneumoconiosis(OR: 0.002, 95% CI: 7.58×10-5–0.037, p = 5.18×10-5), Asthma (OR: 0.706, 95% CI:0.601–0.829, p = 2.22×10-5) and T2DM (OR: 0.457, 95% CI: 0.253–0.823, p = 9.13×10-3) (Supplementary Table S4). Here, SLC5A2 is linked to interstitial lung disease.